Press coverage about Tocagen (NASDAQ:TOCA) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tocagen earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.1124877549417 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- EPS for Tocagen Inc. (TOCA) forecasted at $-0.57 (thecasualsmart.com)
- Tocagen (TOCA) Given Average Recommendation of “Buy” by Analysts (americanbankingnews.com)
- Tocagen Presents Preliminary Toca 6 Phase 1 Data in Patients with Advanced Solid Tumors at the American … (prnewswire.com)
- Tocagen Presents Preliminary Toca 6 Phase 1 Data in Patients with Advanced Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting 2018 (finance.yahoo.com)
- This Day That Year: Tocagen (nasdaq.com)
Shares of TOCA traded up $0.55 during trading hours on Wednesday, reaching $10.77. The company’s stock had a trading volume of 70,863 shares, compared to its average volume of 127,024. The company has a market capitalization of $204.09 and a price-to-earnings ratio of -4.08. Tocagen has a 1-year low of $8.60 and a 1-year high of $17.95. The company has a debt-to-equity ratio of 0.05, a current ratio of 5.23 and a quick ratio of 5.23.
Tocagen (NASDAQ:TOCA) last issued its earnings results on Thursday, March 8th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.02). The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.01 million. Tocagen had a negative net margin of 94,948.78% and a negative return on equity of 145.76%. equities research analysts expect that Tocagen will post -2.3 earnings per share for the current fiscal year.
Several research firms have issued reports on TOCA. BidaskClub upgraded Tocagen from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Zacks Investment Research upgraded Tocagen from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a report on Wednesday, March 14th. Finally, ValuEngine upgraded Tocagen from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $21.50.
WARNING: This article was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.thelincolnianonline.com/2018/04/18/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-tocagen-toca-share-price.html.
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.